Catalent Experts To Speak At Pharma Integrates 2012




Catalent Experts to Speak on Clinical Outsourcing, Supply Chain Management and Choosing Outsourcing Partners at Pharma Integrates 2012

Somerset, NJ, November 20 2012 – Experts from Catalent Pharma Solutions will be among the speakers at the forthcoming Pharma Integrates conference, on the 28th and 29th November at the Riverbank Park Plaza Hotel, London, UK.  At the conference, bio/pharmaceutical procurement and outsourcing professionals will consider how they see partnerships strategically.
 
On the 28th, Catalent’s Nick Page, Vice President of Operations, Modified Release Technologies, will participate in the panel discussion “Total Supply Chain Management - Harmonising & Sharing Best Practice”. On the following day Mr. Page will co-present “Choosing Partners in an Era of Consolidation”, with Sherman Whitfield, President, Strategic Alliance Consulting. Their presentations will cover the development of a corporate strategy for partnering along with the risks involved in partnering and will also look at examples of why partnerships failed, predicting and preparing for uncertainty in partnership and tools for partnership management.
On the 29th, Gerry Hepburn, COO, and General Manager of Catalent’s Clinical Supply Operations, will jointly host the “Clinical Outsourcing Strategies” session with Dr. Erik Kwidzinski, Associate Director, Portfolio Management Clinical Logistics Services, PAREXEL. Their presentations will examine ways to drive clinical innovation without compromising quality, aligning productivity strategies to address clinical challenges and business imperatives and creating effective oversight strategies. The recently announced Global Alliance between Catalent Pharma Solutions and PAREXEL will be highlighted as one example of an innovative solution to improving efficiency in the development process.
 
Nick Page has over 30 years of experience in primary and secondary pharmaceutical manufacturing and packaging covering a wide range of products and dosage forms. He is currently VP of Operations for Catalent’s modified release technology (MRT) business unit with multi-site responsibility for the manufacture and supply of Catalent’s leading MRT product portfolio including Zydis®, their proprietary fast-dissolve technology.
Mr. Hepburn has 30 years’ experience in engineering, operations and management and is currently responsible for Catalent’s global clinical trials supply business including comparator sourcing, clinical packaging and labeling, and the storage, shipment, tracking and return of clinical trials materials.
For further information and to register, please visit www.lifesciencesindex.com/pharma-integrates-2012 .

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.

more products. better treatments. reliably supplied.™